Judge Delays SEC Settlement With Elon Musk Over Twitter Stock Disclosure Case 
U.S.-China Beef Trade Deal Hopes Rise Ahead of Trump-Xi Summit 
Dollar Rises as Strait of Hormuz Crisis Pushes Oil Prices Higher 
Armani Group Eyes Strategic Stake Sale to Luxury Giants 
OCBC Q1 Profit Rises 5% on Strong Wealth Management and Non-Interest Income 
Asian Currencies Slip as US Dollar Gains on Rising Iran Tensions and Awaited Jobs Data 
Continental AG Shares Jump After Q1 Profit Beats Expectations 
TikTok Nears $400 Million Settlement With Trump Administration Over Child Privacy Lawsuit 
AI-Driven Inflation Raises U.S. Consumer Prices, Goldman Sachs Says 
Hantavirus Cruise Ship Outbreak Triggers Global Health Alert 
European Stocks Fall as US-Iran Conflict Rekindles Energy Supply Fears 
Trump Invites Top CEOs Including Nvidia, Apple, Boeing to China Summit With Xi Jinping 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
AWS Data Center Overheating Disrupts Cloud Services in Northern Virginia 
China Inflation Jumps as Iran Conflict Drives Energy Costs Higher 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Australia Budget 2026: Smaller Deficit Expected Amid Tax Reform Push 
Samsung Group is currently negotiating to acquire Biogen Inc., the American biotech company headquartered in Cambridge, Massachusetts. If the talks turn out to be successful, it will be the South Korean manufacturing conglomerate's biggest transaction ever.
Samsung Group is really interested in the mega-deal proposal from Biogen Inc., and this is set to become its largest acquisition. In 2016, the company set a record for its largest transaction ever after buying Harman, an American electronics systems maker for vehicles, for $8 billion. Now, its possible acquisition of the biotech firm will top this amount by more than five times over.
According to The Korea Economic Daily, Biogen Inc. spoke to Samsung to offer some of its shares that could be worth over ₩50 trillion or about $42 billion, including the control premium. The biotech firm's market cap at the moment is moderately less than $35 billion.
An investment banking source revealed on Wednesday, Dec. 29, that Samsung Group may buy the US-based drugmaker that specializes in neurological diseases, including dementia and Alzheimer's. "Samsung is at the negotiating table with the sell-side to acquire Biogen," a senior official at a global investment bank told KED.
In case the stake acquisition turns out to be successful, Samsung will become one of the top-ranking global biotechnology companies. It will also be able to expand its pharmaceutical business and do more aside from biosimilar treatment drugs and manufacturing deals. As for Biogen, it is also expected to steadily make high operating profits once the deal is sealed.
"Samsung is nurturing bio business as a new growth engine," another insider stated. "Acquiring Biogen will create an opportunity to take a quantum leap."
If the acquisition talks failed, it was reported that Samsung would attempt to buy back the remaining stake owned by Biogen in Samsung Bioepis, their biosimilar joint venture. Meanwhile, the response to the acquisition news was good so far as Biogen's stock went up after the report was published.
Market Watch reported that Biogen's shares increased 8.9 percent in the afternoon trading on Wednesday, just after it was reported that Samsung Group is on the negotiation table with the US-based drugmaker to purchase stakes in the company that is valued at around $42 billion.
